Physician profile

Herbert M Green

Internal Medicine · Port Jervis, NY

NPI 1619919552

$5,580.85

in general payments reported to CMS, 2019-2025

24 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Pharmaceuticals, INC $907.11 2019-2022
Novo Nordisk INC $793.12 2019-2021
Astrazeneca Pharmaceuticals LP $577.45 2019-2022
Boehringer Ingelheim Pharmaceuticals, INC. $461.73 2019-2021
Lilly USA, LLC $434.34 2019-2021
Allergan, INC. $419.77 2019-2020
Glaxosmithkline, LLC. $393.08 2019-2021
Pfizer INC. $357.70 2019-2021
Amgen INC. $333.65 2019-2021
Amarin Pharma, INC. $203.85 2019-2021
Astellas Pharma US INC $149.07 2019-2021
Abbvie INC. $127.98 2021-2022
Takeda Pharmaceuticals U.S.A., INC. $84.37 2019-2021
E.R. Squibb & Sons, L.L.C. $63.25 2019-2020
Novartis Pharmaceuticals Corporation $63.02 2019
Show all 24 companies
CompanyGeneral paymentsYearsTop products
Sanofi-Aventis U.S. LLC $49.65 2019
Regeneron Healthcare Solutions, INC. $40.41 2019
Circassia INC. $24.37 2019
Corcept Therapeutics $22.76 2019
Esperion Therapeutics, INC. $20.71 2021
Mylan Specialty L.P. $15.26 2019
Kowa Pharmaceuticals America, INC. $13.93 2019
Teva Pharmaceuticals USA, INC. $12.29 2020
Merck Sharp & Dohme LLC $11.98 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Herbert M Green

$5,580.85

in general payments reported 2019-2025

Years
2019-2022
Top company
Janssen Pharmaceuticals, INC

https://glasscript.com/doctor/345294/herbert-m-green

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.